

Amir A Jazaeri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9257234/publications.pdf>

Version: 2024-02-01

90
papers

5,064
citations

159525

30
h-index

95218

68
g-index

92
all docs

92
docs citations

92
times ranked

7252
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10393-10398.	3.3	1,796
2	Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2002, 94, 990-1000.	3.0	260
3	Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2002, 4, R3.	2.2	186
4	Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers. <i>Clinical Cancer Research</i> , 2005, 11, 6300-6310.	3.2	175
5	The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. <i>Cell Cycle</i> , 2010, 9, 4387-4398.	1.3	152
6	CRL4Cdt2 E3 Ubiquitin Ligase Monoubiquitinates PCNA to Promote Translesion DNA Synthesis. <i>Molecular Cell</i> , 2010, 37, 143-149.	4.5	135
7	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. , 2019, 7, 93.		131
8	Frailty: An outcome predictor for elderly gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2012, 126, 20-24.	0.6	112
9	Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). <i>Gynecologic Oncology</i> , 2020, 157, 161-166.	0.6	106
10	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. , 2019, 7, 31.		94
11	Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. <i>Molecular Carcinogenesis</i> , 2003, 36, 53-59.	1.3	83
12	Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. <i>Clinical Cancer Research</i> , 2003, 9, 4811-8.	3.2	73
13	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. <i>Cell Reports</i> , 2020, 31, 107502.	2.9	69
14	Molecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma. <i>Neoplasia</i> , 2011, 13, 899-IN16.	2.3	66
15	Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1958-1967.	1.9	60
16	SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. <i>Genome Biology</i> , 2014, 15, 443.	3.8	59
17	Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. <i>Frontiers in Immunology</i> , 2017, 8, 689.	2.2	55
18	Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. <i>Oncogene</i> , 2001, 20, 6965-6969.	2.6	52

#	ARTICLE	IF	CITATIONS
19	Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 568-574.	0.7	51
20	Olfactory bulb organization and development in <i>Monodelphis domestica</i> (grey short-tailed opossum). <i>Journal of Comparative Neurology</i> , 1992, 320, 544-554.	0.9	48
21	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1080-1086.	0.7	48
22	Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. <i>Gynecologic Oncology</i> , 2019, 155, 237-244.	0.6	48
23	Immunotherapy in Gynecologic Cancers: Are We There Yet?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 59.	1.3	45
24	Cyclooxygenase-2 in cervical neoplasia: A review. <i>Gynecologic Oncology</i> , 2008, 109, 140-145.	0.6	44
25	Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 199.e1-199.e5.	0.7	43
26	Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. <i>Gynecologic Oncology</i> , 2020, 158, 570-575.	0.6	43
27	Core Biopsies Can Be Used to Distinguish Differences in Expression Profiling by cDNA Microarrays. <i>Journal of Molecular Diagnostics</i> , 2002, 4, 30-36.	1.2	41
28	Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 4599-4611.	0.4	39
29	Expression of Estrogen Receptor β mRNA and Protein Variants in Human Endometrial Carcinoma. <i>Gynecologic Oncology</i> , 1999, 74, 38-47.	0.6	38
30	The utility of HPV DNA triage in the management of cytological AGC. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 559-565.	0.7	37
31	Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. <i>Science Advances</i> , 2022, 8, eabm1032.	4.7	35
32	MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. <i>Statistics in Medicine</i> , 2016, 35, 3892-3906.	0.8	34
33	Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 2102.	2.2	33
34	Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. <i>Frontiers in Immunology</i> , 2019, 10, 2410.	2.2	33
35	Estrogen Receptor mRNA Splice Variants in Pre- and Postmenopausal Human Endometrium and Endometrial Carcinoma. <i>Gynecologic Oncology</i> , 1997, 65, 149-157.	0.6	31
36	Inhibition of $\alpha_4\beta_1$ integrin increases ovarian cancer response to carboplatin. <i>Gynecologic Oncology</i> , 2014, 132, 455-461.	0.6	31

#	ARTICLE	IF	CITATIONS
37	Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. <i>Cancers</i> , 2021, 13, 946.	1.7	31
38	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6354-6365.	3.2	31
39	A Clinical and Biological Comparison Between Malignant Mixed Müllerian Tumors and Grade 3 Endometrioid Endometrial Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 261-265.	1.2	28
40	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. <i>Gynecologic Oncology</i> , 2016, 141, 86-94.	0.6	26
41	Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. , 2019, 7, 118.		26
42	Evaluation of EVI1 and EVI1s (p324) as potential therapeutic targets in ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 118, 189-195.	0.6	24
43	Appendiceal Pathology at the Time of Oophorectomy for Ovarian Neoplasms. <i>Obstetrics and Gynecology</i> , 2010, 116, 1348-1353.	1.2	24
44	A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. <i>Gynecologic Oncology</i> , 2008, 108, 77-83.	0.6	23
45	BRCA1-mediated repression of select X chromosome genes. <i>Journal of Translational Medicine</i> , 2004, 2, 32.	1.8	22
46	Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2293-2305.	0.9	22
47	Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. <i>Molecular Oncology</i> , 2009, 3, 151-156.	2.1	21
48	Cervical adenocarcinoma in situ: the predictive value of conization margin status. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 195.e1-195.e8.	0.7	20
49	Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. <i>Neoplasia</i> , 2015, 17, 826-838.	2.3	20
50	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. <i>Scientific Reports</i> , 2021, 11, 3667.	1.6	20
51	A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. <i>PLoS ONE</i> , 2021, 16, e0247905.	1.1	20
52	Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, 24-31.	0.6	20
53	Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 1119-1126.	0.7	19
54	Temozolomide in Advanced and Recurrent Uterine Leiomyosarcoma and Correlation With O6-Methylguanine DNA Methyltransferase Expression. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 120-125.	1.2	19

#	ARTICLE	IF	CITATIONS
55	Potential immunotherapy targets in recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2017, 145, 462-468.	0.6	19
56	The development of serotonergic projections to the olfactory bulb of <i>Monodelphis domestica</i> (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.1	17
57	Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. <i>Cancer Journal (Sudbury, Tj ETQq1 1,0,784314 rgBT /O</i>	1.0	17
58	Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. <i>Gynecologic Oncology</i> , 2018, 151, 407-413.	0.6	17
59	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1747-1757.	2.0	16
60	Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1515-1526.	2.0	14
61	Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. <i>Oncotarget</i> , 2015, 6, 30194-30211.	0.8	14
62	SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 1777.	1.7	13
63	Expression of B7â€“H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. <i>Human Pathology</i> , 2021, 113, 20-27.	1.1	13
64	A nomogram for estimating the probability of ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 2-7.	0.6	12
65	Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. <i>Cancer Discovery</i> , 2021, 11, 560-574.	7.7	12
66	Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens. <i>Journal of Visualized Experiments</i> , 2014, , .	0.2	10
67	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. <i>Cancer Immunology Research</i> , 2022, 10, 259-271.	1.6	10
68	Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 265-267.	1.1	8
69	Sub-terahertz vibrational spectroscopy for microRNA based diagnostic of ovarian cancer. <i>Convergent Science Physical Oncology</i> , 2016, 2, 045001.	2.6	8
70	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021, 39, 829-835.	1.2	8
71	Utilization of a uniform grading system for interpreting serous ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 189.e1-189.e6.	0.7	7
72	Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era. <i>Gynecologic Oncology Case Reports</i> , 2013, 5, 6-9.	0.9	7

#	ARTICLE	IF	CITATIONS
73	Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2022, 165, 664-670.	0.6	7
74	A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5522-5522.	0.8	6
75	Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction. <i>Abdominal Radiology</i> , 2021, 46, 4489-4498.	1.0	5
76	The promise of antiangiogenic therapy for ovarian cancer. <i>Cancer Biology and Therapy</i> , 2009, 8, 2271-2272.	1.5	3
77	B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature. <i>Gynecologic Oncology Reports</i> , 2019, 29, 94-97.	0.3	3
78	Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, 65-71.	0.6	3
79	Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 92-97.	1.2	3
80	An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinum-resistant epithelial ovarian cancer. , 2019, , .		2
81	Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. <i>Journal of Surgical Oncology</i> , 2021, 124, 699-703.	0.8	2
82	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. <i>Gynecologic Oncology</i> , 2018, 151, 374-380.	0.6	1
83	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. <i>Journal of Cancer Education</i> , 2020, , 1.	0.6	1
84	Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1408-1409.	1.2	1
85	Immuno-oncology for Gynecologic Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 149-182.	0.8	1
86	Immuno-Oncology for Gynecologic Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 193-232.	0.8	1
87	First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2679-TPS2679.	0.8	1
88	Sunset, or dawn of a new age for ovarian cancer vaccine therapy?. <i>Gynecologic Oncology</i> , 2019, 155, 387-388.	0.6	0
89	Abstract 3380: Overcoming platinum resistance in ovarian cancer using the novel compound MLN4924.. , 2013, , .		0
90	Abstract 3912: GDF2 promotes anoikis susceptibility in ovarian and breast epithelia. , 2015, , .		0